| Followers | 45 |
| Posts | 129 |
| Boards Moderated | 0 |
| Alias Born | 03/02/2021 |
Wednesday, February 19, 2025 6:04:23 PM
I don't give credence to things I can't verify myself unless the source has proven to be highly trustworthy, so I personally do not put much stock in those reports. Also, even if it were the case that some kind of activity related to inspections were taking place in January, I don't think that would have prevented the second CHM meeting from occurring in December. The consistency of the 6-month gap between CHM meetings 1 and 2, along with the variable amount of time between CHM meeting 2 and approval, indicates to me that the date of the second meeting is set based on a statutory timeline rather than being held after the conclusion of the second phase of review of the MAA. That is, if a second meeting is necessary then it will be held 6 months after the first meeting, regardless of how much work is left to do.
Approximately 3 weeks post-CHM meeting #2 seems to be minimum amount of time to hear approval news. For medicines that take longer, sometimes a 3rd CHM meeting happens, while other times it does not. Sometimes it takes less time (like 5-ish weeks post CHM #2), while other times it can take many months (up to 6 months post-CHM #2 at the absolute longest). To me, this indicates that whatever happens post-CHM meeting 2 depends on the nuances of each application. But the evidence also suggests that, regardless of what happens post-CHM meeting 2, that 6-month gap is consistent. So unless and until other tangible evidence emerges, that's what I personally feel more comfortable basing my opinions on.
Approximately 3 weeks post-CHM meeting #2 seems to be minimum amount of time to hear approval news. For medicines that take longer, sometimes a 3rd CHM meeting happens, while other times it does not. Sometimes it takes less time (like 5-ish weeks post CHM #2), while other times it can take many months (up to 6 months post-CHM #2 at the absolute longest). To me, this indicates that whatever happens post-CHM meeting 2 depends on the nuances of each application. But the evidence also suggests that, regardless of what happens post-CHM meeting 2, that 6-month gap is consistent. So unless and until other tangible evidence emerges, that's what I personally feel more comfortable basing my opinions on.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
